Akebia Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $183.36M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 9, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 5, 2026 | After market close | $49.10M | $-0.03 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 7, 2026 | Before market open | $53.50M | $-0.03 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 26, 2026 | Before market open | $57.60M | $-0.05 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 10, 2025 | Before market open | $58.80M | $0.00 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 7, 2025 | Before market open | $62.50M | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 8, 2025 | Before market open | $57.30M | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 13, 2025 | Before market open | $46.50M | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 7, 2024 | Before market open | $37.40M | $-0.10 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 8, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 9, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 14, 2024 | After market close | – | – | – |
Company guidance
Outlook given with results on Jan 12, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| Vafseo net product revenue | Q4 2025 | $5.00M to $6.00M | New |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Akebia Therapeutics filed with the SEC
Akebia Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights
Results of operations · EX-99.1 to Form 8-K
U.S. Renal Care and Akebia Announce Interim Analysis of VOICE Trial Demonstrated Overwhelming Statistical Evidence of Improved Safety Outcomes for Patients Treated with Vafseo versus an ESA
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Akebia Therapeutics Reports First Quarter 2026 Financial Results and Commercial and
Results of operations · EX-99.1 to Form 8-K
Akebia Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial and Pipeline Highlights
Results of operations · EX-99.1 to Form 8-K
Akebia Therapeutics Announces Corporate Updates and 2026 Pipeline Outlook
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Akebia Announces Establishment of Rare Kidney Disease Pipeline
Material agreement · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Akebia Therapeutics Reports Third Quarter 2025 Financial Results
Results of operations · EX-99 to Form 8-K
Akebia Therapeutics Provides Update on Vafseo for Non-Dialysis Patients
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Akebia Therapeutics Reports Second Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Akebia Therapeutics Reports First Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Akebia Therapeutics Announces Pricing of Public Offering of Common Stock
Material agreement · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Akebia Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Vafseo® (vadadustat) Commercial Launch Progress Update
Results of operations · EX-99.1 to Form 8-K
We believe we are positioned to succeed in the dialysis market…. …and to chart a path to capitalize on significantly larger non-dialysis market opportunity.
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Akebia Therapeutics Reports Third Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Akebia Therapeutics Signs Commercial Supply Contract with Leading Dialysis Organization to Enable Access to Vafseo® (vadadustat) for Patients on Dialysis
Regulation FD disclosure · EX-99 to Form 8-K
Akebia Therapeutics Reports Second Quarter 2024 Financial Results
Results of operations · EX-99 to Form 8-K
Akebia Therapeutics Reports First Quarter 2024 Financial Results
Results of operations · EX-99 to Form 8-K
Akebia Receives FDA Approval of Vafseo® (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Akebia Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Unlocking the Power of the Hypoxia- Inducible Factor (HIF) Pathway Delivering Innovation for Patients with Chronic Kidney Disease (CKD) January 2024 Nasdaq: AKBA 1
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Akebia Therapeutics Reports Third Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Akebia Receives FDA Acceptance of Resubmission to NDA of
Regulation FD disclosure · EX-99.1 to Form 8-K
Akebia Announces Approval of Vafseo ® (vadadustat) in Australia and
Regulation FD disclosure · EX-99.1 to Form 8-K
Akebia Therapeutics Reports Second Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Akebia Therapeutics Provides Update on Form 10-Q Filing
Regulation FD disclosure · EX-99.1 to Form 8-K
Akebia Therapeutics Completed Type A Meeting with the FDA and Expects to Resubmit Vadadustat NDA in Third Quarter 2023
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Commercial Depth. Operational Excellence. A Commitment to Advance Innovation to Address Unmet Needs. John P. Butler, CEO June 2023 Exhibit 99.1
Regulation FD disclosure · EX-99.1 to Form 8-K
FDA Provides Akebia Therapeutics a Path Forward for Vadadustat
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Akebia Therapeutics Enters into License Agreement with Medice Arzneimittel Pütter GmbH&Co.KG for the Commercialization of Vafseo ® for the Treatment of Anemia associated with CKD in Europe and Australia
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Akebia Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
Other events · EX-99.1 to Form 8-K
Akebia Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights
Results of operations · EX-99.1 to Form 8-K
Akebia Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and
Results of operations · EX-99.1 to Form 8-K
Akebia Therapeutics Received Interim Response from the FDA to Appeal for Vadadustat
Other events · EX-99.1 to Form 8-K
Excellence. A Commitment to Advance Innovation to Address Unmet Needs. John P. Butler, CEO David A. Spellman, CFO Mercedes Carrasco, IR & Corp Comm January 2023 Exhibit 99.1
Regulation FD disclosure · EX-99.1 to Form 8-K
Akebia Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights
Results of operations · EX-99.1 to Form 8-K
Akebia Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Akebia Therapeutics Announces Initial Findings from Investigator-Sponsored Clinical
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Akebia Therapeutics Reports First Quarter 2022 Financial Results and Business Update
Results of operations · EX-99.1 to Form 8-K
Akebia Therapeutics Receives Complete Response Letter from the FDA for Vadadustat for the Treatment of
Other events · EX-99.1 to Form 8-K